Multiple myeloma is a cancer of the bone marrow plasma cells. It is synonymous with "myeloma" and "plasma cell myeloma." Plasma cells make antibodies against infectious agents such as viruses and bacteria. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is called “multiple” because there are frequently multiple patches or areas in bone marrow where it grows.

Breadcrumb

Brian G.M. Durie Outstanding Achievement Award

The Brian G.M. Durie Outstanding Achievement Award was first presented on June 12, 2018. Named for IMF Chairman Dr. Brian Durie, this award recognizes excellence in multiple myeloma research. Dr. Durie is also the Medical Director for AMyC and Specialist in Multiple Myeloma and Related Disorders for Cedars-Sinai Outpatient Cancer Center in Los Angeles, California. He is Co-Chair of the Myeloma Committee for SWOG.

This Year's Recipient:

María Victoria Mateos, MD

Dr. María-Victoria Mateos, is Associate Professor of Hematology and Consultant Physician in the Haematology Department at the University of Salamanca and Director of the Myeloma Unit, where she is responsible for coordinating the Clinical Trials Unit in Salamanca University Hospital’s Haematology Department. She currently serves on the European Hematology Association (EHA) as the chair of Scientific Program Committee for the 2019 congress.

“It is a great honor for me to receive this prestigious award, which recognizes the clinical research we have been doing in myeloma with a key objective—to try to cure, or at least to improve, the outcome of our patients,” said Dr. Mateos. “This award belongs to every Spanish investigator in the Spanish Myeloma Group. Without their contributions, generosity and help, none of the achievements would have been possible.”

b

Image Right

White

Previous Recipients:

Sigurdur Yngvi Kristinsson, MD

Dr. Sigurdur Yngvi Kristinsson, Professor of Hematology at the University of Iceland and specialist in internal medicine and hematology at the Landspitali University Hospital in Iceland, is the recipient of the inaugural Brian G.M. Durie Outstanding Achievement Award. Dr. Kristinsson serves as principal investigator for Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM®), a population-based MGUS and multiple myeloma screening study. He has led several large population-based myeloma studies in collaboration with major research centers and is a frequent speaker at international hematology conferences.

“Myeloma patients around the world have benefited—and will continue to benefit—from the important research contributions made by Dr. Kristinsson,” said Dr. Durie. “His work brings us closer to finding the pathway to a cure.”